Related Experiment Video
Updated: Mar 27, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
11.1K
Combined small-cell lung carcinoma: An institutional experience
Audrey S Wallace1, Monika Arya2, Shellaine R Frazier3
1University of Missouri, School of Medicine Columbia, MO, USA.
Thoracic Cancer
|January 15, 2016
Summary
This study on combined small-cell lung cancer (SCLC) found that advanced stage and poor performance status significantly impact survival. Early detection and treatment may improve outcomes for patients with this rare lung cancer subtype.
Area of Science:
- Oncology
- Pulmonology
- Medical Research
Background:
- Combined small-cell lung cancer (SCLC) is a rare histological subtype of lung cancer.
- Understanding prognostic factors is crucial for managing patients with combined SCLC.
Purpose of the Study:
- To identify prognostic factors and analyze survival rates in patients diagnosed with combined SCLC.
- To evaluate the impact of disease stage, comorbidities, and performance status on patient outcomes.
Main Methods:
- Retrospective review of 41 patients with combined SCLC treated between 1995 and 2010.
- Data collected included demographics, diagnosis, disease characteristics, treatment, and survival.
- Kaplan-Meier analysis was used for survival estimates, with statistical significance set at P < 0.05.
Main Results:
- Median age was 68; 57% were female. 94% had a history of smoking, and 80% had comorbidities.
- 28 patients had SCLC/large cell carcinoma, 7 had SCLC/adenocarcinoma or SCLC/squamous cell carcinoma.
- Median survival was 15.4 months for AJCC stages I-III and 3.4 months for stage IV. Improved survival was linked to ECOG performance status <2 and no weight loss.
Conclusions:
- Advanced stage combined SCLC is associated with a poor prognosis, similar to pure SCLC.
- Novel chemotherapeutic agents or targeted therapies may offer improved outcomes for future combined SCLC patient cohorts.
